摘要
目的 探讨肺表面活性物质治疗新生儿重症肺炎的有效性及安全性.方法 选取2015年4月至2016年4月重症肺炎新生儿57例,依照入院时间随机分成观察组30例和对照组27例.对照组行常规治疗,观察组在常规综合治疗基础上加用肺表面活性物质,比较两组临床疗效.结果 治疗后,观察组症状和体征消失时间、机械通气时间及住院时间均少于对照组,差异有统计学意义（P〈0.05）.观察组临床总有效率为86.6%（26/30）,高于对照组的70.3%（19/27）,差异有统计意义（P〈0.05）.结论 肺表面活性物质可有效提高新生儿重症肺炎临床疗效,且安全性较好.
Objective To investigate the safety and efficacy of pulmonary surfactant on neonatal severe pneumonia.Methods A total of 57 neonatal with severe pneumonia from April 2015 to April 2016 were selected, and were divided into the observation group （30 cases） and the control group （27 cases） according to the admission time.The control group was given routine treatment, and the observation group given pulmonary surfactant therapy on the basis of the control group.The efficacy was compared between the two groups.Results After treatment, the symptoms and signs disappeared time, the time of mechanical ventilation, and the length of hospital stay of the observation group were less than those of the control group, the differences were significant（P〈0.05）.The total effective rate of the observation group was 86.6% （26/30）, and which was higher than that of the control group [70.3%（19/27）], the difference was significant（P〈0.05）.Conclusions Pulmonary surfactant for neonatal severe pneumonia can improve the clinical efficacy, and the security is better.
出处
《中国实用医刊》
2017年第9期103-104,共2页
Chinese Journal of Practical Medicine
